FS MDPI

DRUG4 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

AsthmaPersistent Asthma

Phase 2

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

CompletedNCT01772368

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2013-01-31End: 2013-06-30Updated: 2017-06-12

Phase 3

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

CompletedNCT02139644

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2014-06-30End: 2015-09-30Updated: 2021-11-12

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

CompletedNCT02141854

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2014-06-30End: 2015-09-30Updated: 2021-11-09

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

CompletedNCT02175771

Teva Branded Pharmaceutical Products R&D, Inc.Persistent Asthma

Start: 2014-07-31End: 2015-07-31Updated: 2021-11-09

Related Papers

Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.

2017-06-219 citations

A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma

Allergy and Asthma Proceedings2017-05-2514 citations

Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma

Allergy and Asthma Proceedings2016-05-2411 citations